FDA’s FY 2013 Drug GMP Warning Letters
This article was originally published in The Gold Sheet
Executive Summary
Topicals and injectables were the most common types of products to receive drug GMP warning letters in FY 2013. All 43 warning letters are listed here by dosage form with the key issues described.
You may also be interested in...
US Patients Continue To Overpay For Off-Patent Drugs Despite $373bn In Savings
The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines.
Shortlist Unveiled For GGB Awards
The final shortlist of contenders has been unveiled for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt on 2 November.
GDUFA Research Impacting Generic Development, ANDA Approvals
Increases in approved ANDAs that were affected by GDUFA research shows the importance of the US FDA’s regulatory science program.